MA44934A1 - Thérapie combinée - Google Patents

Thérapie combinée

Info

Publication number
MA44934A1
MA44934A1 MA44934A MA44934A MA44934A1 MA 44934 A1 MA44934 A1 MA 44934A1 MA 44934 A MA44934 A MA 44934A MA 44934 A MA44934 A MA 44934A MA 44934 A1 MA44934 A1 MA 44934A1
Authority
MA
Morocco
Prior art keywords
inhibitor
patient
raf inhibitor
tumor sample
genetic alterations
Prior art date
Application number
MA44934A
Other languages
English (en)
Other versions
MA44934B1 (fr
Inventor
Giordano Caponigro
Darrin Stuart
Parseval Laure De
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50439443&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA44934(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA44934A1 publication Critical patent/MA44934A1/fr
Publication of MA44934B1 publication Critical patent/MA44934B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Abstract

La présente invention concerne une méthode consistant à neutraliser la résistance à un inhibiteur de b-raf en vue du traitement d'une maladie proliférative, ladite méthode comprenant les étapes consistant à prélever un échantillon tumoral chez le patient et à y rechercher des altérations génétiques au sein d'un ensemble de gènes comprenant braf, craf, ccnd1, cdk4, her2, igf-1r, cmet, fgfr1, fgfr2, fgfr3 egfr, map2k1, map2k2, nras, kras hras, pten, pik3ca et p16, puis à administrer au patient un traitement médicamenteux combiné comprenant l'inhibiteur de b-raf et un second inhibiteur capable de surmonter la résistance à l'inhibiteur de b-raf, ledit second inhibiteur étant choisi sur la base des altérations génétiques découvertes dans l'échantillon tumoral.
MA44934A 2013-03-21 2014-03-19 Therapie de combinaison comprenant un inhibiteur de b-raf et un second inhibiteur MA44934B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361804056P 2013-03-21 2013-03-21
PCT/IB2014/059975 WO2014147573A2 (fr) 2013-03-21 2014-03-19 Thérapie combinée

Publications (2)

Publication Number Publication Date
MA44934A1 true MA44934A1 (fr) 2020-01-31
MA44934B1 MA44934B1 (fr) 2021-11-30

Family

ID=50439443

Family Applications (2)

Application Number Title Priority Date Filing Date
MA44934A MA44934B1 (fr) 2013-03-21 2014-03-19 Therapie de combinaison comprenant un inhibiteur de b-raf et un second inhibiteur
MA38522A MA38522A1 (fr) 2013-03-21 2014-03-19 Thérapie de combinaison comprenant un inhibiteur de b-raf et un second inhibiteur.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA38522A MA38522A1 (fr) 2013-03-21 2014-03-19 Thérapie de combinaison comprenant un inhibiteur de b-raf et un second inhibiteur.

Country Status (34)

Country Link
US (3) US9913844B2 (fr)
EP (1) EP2976106B1 (fr)
JP (2) JP6449234B2 (fr)
KR (2) KR102258698B1 (fr)
CN (2) CN105209073A (fr)
AR (1) AR095699A1 (fr)
AU (1) AU2014233805B2 (fr)
BR (1) BR112015023483B8 (fr)
CA (1) CA2907704C (fr)
CL (2) CL2015002807A1 (fr)
CY (1) CY1124776T1 (fr)
DK (1) DK2976106T3 (fr)
EA (1) EA201591842A1 (fr)
ES (1) ES2870716T3 (fr)
GT (1) GT201500249A (fr)
HK (1) HK1214135A1 (fr)
HU (1) HUE055072T2 (fr)
IL (2) IL241188B (fr)
JO (1) JOP20140128B1 (fr)
MA (2) MA44934B1 (fr)
MX (1) MX2015013466A (fr)
MY (1) MY181085A (fr)
NZ (1) NZ712184A (fr)
PE (1) PE20151785A1 (fr)
PH (1) PH12015502040A1 (fr)
PL (1) PL2976106T3 (fr)
PT (1) PT2976106T (fr)
SG (2) SG11201507730UA (fr)
SI (1) SI2976106T1 (fr)
TN (1) TN2015000389A1 (fr)
TW (1) TWI603734B (fr)
UA (1) UA118846C2 (fr)
WO (1) WO2014147573A2 (fr)
ZA (1) ZA201800424B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014233805B2 (en) 2013-03-21 2018-10-18 Array Biopharma Inc. Combination therapy comprising a B-Raf inhibitor and a second inhibitor
JP2017517558A (ja) * 2014-06-13 2017-06-29 ジェネンテック， インコーポレイテッド 癌薬剤耐性の治療方法及び防止方法
CN105753869B (zh) * 2015-04-01 2018-09-25 苏州晶云药物科技有限公司 一种cdk抑制剂和mek抑制剂的共晶及其制备方法
PL3283058T3 (pl) * 2015-04-16 2023-03-20 Novartis Ag Tabletka rybocyklibu
US9814714B2 (en) * 2015-05-22 2017-11-14 Plexxikon Inc. Kinase modulation, and indications therefor
CN105732642B (zh) * 2015-11-18 2018-09-25 苏州晶云药物科技有限公司 一种cdk抑制剂和mek抑制剂的共晶及其制备方法
CA3013845A1 (fr) * 2016-02-19 2017-08-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methodes pour le traitement du spectre de surcroissance lie au pik3ca
CR20190002A (es) 2016-06-03 2019-06-10 Zhu Alexander Cao Combinaciones farmacéuticas
CN107058565A (zh) * 2016-08-31 2017-08-18 郭军 肢端型黑色素瘤的诊断和治疗
BR112019005046A2 (pt) * 2016-09-19 2019-06-18 Novartis Ag combinações terapêuticas compreendendo um inibidor de raf e um inibidor de erk
EP3559276B1 (fr) 2016-12-20 2022-03-23 ETH Zurich Identification de médicaments ciblant des programmes de tolérance de médicament non-génétiques dans le cancer
WO2018213302A1 (fr) * 2017-05-16 2018-11-22 Biomed Valley Discoveries, Inc. Compositions et procédés pour le traitement du cancer avec mutations de braf atypiques
WO2018218633A1 (fr) * 2017-06-02 2018-12-06 Beijing Percans Oncology Co. Ltd. Polythérapies pour le traitement de cancers
WO2019195959A1 (fr) 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Polythérapie pour cancers à mutation de braf
WO2023212071A1 (fr) * 2022-04-26 2023-11-02 Beigene Switzerland Gmbh Combinaison et utilisation associée
WO2023230554A1 (fr) 2022-05-25 2023-11-30 Pfizer Inc. Combinaison d'un inhibiteur de braf, d'un inhibiteur d'egfr et d'un antagoniste de pd-1 pour le traitement du cancer colorectal msi-h/dmmr, avec mutation v600e de braf
WO2023240178A1 (fr) * 2022-06-08 2023-12-14 Mapkure, Llc Méthodes de traitement du cancer avec un inhibiteur de b-raf

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2275102E (pt) * 2002-03-13 2015-10-27 Array Biopharma Inc Derivados de benzimidazole alquilado n3 como inibidores de mek
TW200406203A (en) 2002-03-13 2004-05-01 Array Biopharma Inc N3 alkylated banzimidazole derivatives as MEK inhibitors
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
WO2005051301A2 (fr) 2003-11-19 2005-06-09 Array Biopharma Inc. Inhibiteurs heterocycliques de mek et leurs procedes d'utilisation
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
US20060134068A1 (en) 2004-11-09 2006-06-22 Mount Sinai School Of Medicine Of New York University Treatment of cancer by simultaneous inhibiton of BRAF and restoration or mimicry of p16INK4A activity
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
PE20070335A1 (es) 2005-08-30 2007-04-21 Novartis Ag Benzimidazoles sustituidos y metodos para su preparacion
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
TWI398252B (zh) 2006-05-26 2013-06-11 Novartis Ag 吡咯并嘧啶化合物及其用途
BRPI0719112A2 (pt) * 2006-11-20 2013-12-10 Novartis Ag Sais e formas de cristal de 2-metil-2-[4-(3-metil-2-oxo-8-quinolin-3-il-2,3-di-hidro-imi dazo[4,5-c]quinolin-1-il)-fenil]-propionitrila
SI2300455T1 (sl) * 2008-05-21 2017-12-29 Incyte Holdings Corporation Soli 2-fluoro-n-metil-4-(7-(kinolin-6-il-metil)-imidazo(1,2-b)1,2,4) triazin-2-il)benzamid in postopki v zvezi z njihovo pripravo
PL2331547T3 (pl) 2008-08-22 2015-01-30 Novartis Ag Związki pirolopirymidynowe jako inhibitory CDK
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
JO3002B1 (ar) * 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
KR20120097496A (ko) 2009-10-12 2012-09-04 글락소스미스클라인 엘엘씨 조합물
TWI480276B (zh) * 2010-08-27 2015-04-11 Irm Llc 作為蛋白質激酶抑制劑之化合物及組合物
BR112013012485A2 (pt) * 2010-11-19 2016-09-06 Glaxosmithkline Ip No 2 Ltd método de tratamento com inibidor braf
US20130004481A1 (en) * 2011-01-12 2013-01-03 Boehringer Ingelheim International Gmbh Anticancer therapy
WO2012145503A1 (fr) * 2011-04-21 2012-10-26 Novartis Ag Combinaisons pharmaceutiques
WO2012178038A1 (fr) 2011-06-24 2012-12-27 The Broad Institute, Inc. Méthodes de traitement du cancer
EP2570127A1 (fr) 2011-09-16 2013-03-20 Sanofi Compositions et procédés pour traiter le cancer avec un inhibiteur bêta PI3KB et un inhibiteur de la voie MAPK, incluant des inhibiteurs MEK et RAF
SG11201400724SA (en) * 2011-09-19 2014-04-28 Genentech Inc Combination treatments comprising c-met antagonists and b-raf antagonists
AR091876A1 (es) 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
LT2882440T (lt) 2012-08-07 2019-04-25 Novartis Ag Farmaciniai deriniai, apimantys b-raf slopiklį, egfr slopiklį ir nebūtinai pi3k-alfa slopiklį
AU2014233805B2 (en) 2013-03-21 2018-10-18 Array Biopharma Inc. Combination therapy comprising a B-Raf inhibitor and a second inhibitor

Also Published As

Publication number Publication date
US20160296520A1 (en) 2016-10-13
US10548894B2 (en) 2020-02-04
US9913844B2 (en) 2018-03-13
PH12015502040B1 (en) 2016-01-18
TN2015000389A1 (en) 2017-01-03
HUE055072T2 (hu) 2021-10-28
CA2907704A1 (fr) 2014-09-25
IL241188A0 (en) 2015-11-30
AR095699A1 (es) 2015-11-04
PH12015502040A1 (en) 2016-01-18
TWI603734B (zh) 2017-11-01
AU2014233805B2 (en) 2018-10-18
IL272921A (en) 2020-04-30
UA118846C2 (uk) 2019-03-25
IL272921B (en) 2022-10-01
HK1214135A1 (zh) 2016-07-22
MX2015013466A (es) 2016-06-21
KR20210110794A (ko) 2021-09-09
SG10201906270VA (en) 2019-08-27
CA2907704C (fr) 2023-01-10
MA38522A1 (fr) 2017-10-31
KR102446839B1 (ko) 2022-09-23
MY181085A (en) 2020-12-17
CL2018001371A1 (es) 2018-09-07
PT2976106T (pt) 2021-05-26
EP2976106A2 (fr) 2016-01-27
JP6449234B2 (ja) 2019-01-09
MA44934B1 (fr) 2021-11-30
CN112641787A (zh) 2021-04-13
KR102258698B1 (ko) 2021-06-01
BR112015023483A8 (pt) 2019-12-03
CY1124776T1 (el) 2022-11-25
US20180221370A1 (en) 2018-08-09
BR112015023483B8 (pt) 2023-01-31
IL272921B2 (en) 2023-02-01
IL241188B (en) 2021-02-28
GT201500249A (es) 2017-09-01
ES2870716T3 (es) 2021-10-27
CN105209073A (zh) 2015-12-30
SG11201507730UA (en) 2015-10-29
PL2976106T3 (pl) 2021-10-25
US20200246338A1 (en) 2020-08-06
NZ751830A (en) 2020-09-25
BR112015023483A2 (pt) 2017-07-18
JP2016522160A (ja) 2016-07-28
BR112015023483B1 (pt) 2022-07-19
TW201440770A (zh) 2014-11-01
CL2015002807A1 (es) 2016-05-13
DK2976106T3 (da) 2021-06-14
KR20150132205A (ko) 2015-11-25
JP6742391B2 (ja) 2020-08-19
JP2019055978A (ja) 2019-04-11
ZA201800424B (en) 2022-10-26
JOP20140128B1 (ar) 2021-08-17
PE20151785A1 (es) 2015-12-20
WO2014147573A3 (fr) 2014-12-11
NZ712184A (en) 2020-01-31
AU2014233805A1 (en) 2015-10-01
EP2976106B1 (fr) 2021-04-14
SI2976106T1 (sl) 2021-08-31
WO2014147573A2 (fr) 2014-09-25
EA201591842A1 (ru) 2016-01-29

Similar Documents

Publication Publication Date Title
MA44934A1 (fr) Thérapie combinée
Razavi et al. Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors
Sequist et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations
Escudier et al. Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis
Falchook et al. BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer
Ramalingam et al. Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial
Robert et al. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study
Jimeno et al. A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer
Falchook et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
JP2018508469A5 (fr)
Pirazzoli et al. Afatinib plus cetuximab delays resistance compared to single-agent erlotinib or afatinib in mouse models of TKI-naive EGFR L858R-induced lung adenocarcinoma
EP3147285A3 (fr) Composés de purinone en tant qu'inhibiteurs de kinase
Wells Jr et al. Update: the status of clinical trials with kinase inhibitors in thyroid cancer
JP2016536013A (ja) 疾患における変異の経時的な検出
Buck et al. Treatment patterns and health resource utilization among patients diagnosed with early stage resected non–small cell lung cancer at US community oncology practices
JP2014533272A5 (fr)
Von Pawel et al. Phase 2 HERALD study of patritumab (P) with erlotinib (E) in advanced NSCLC subjects
RU2014117707A (ru) Способ лечения пролиферативного заболевания
RU2013126036A (ru) Способ лечения опухолей
Nakagawa et al. 481TiP Checkmate 722: a phase 3 trial of nivolumab with chemotherapy or ipilimumab vs chemotherapy in epidermal growth factor receptor (EGFR)-mutation, T790M-negative stage IV or recurrent non-small cell lung cancer (NSCLC) after EGFR tyrosine kinase inhibitor (TKI) therapy
Giovanni et al. Molecular targeted approaches for advanced BRAF V600, N-RAS, c-KIT, and GNAQ melanomas
RU2014109999A (ru) Противоопухолевый агент и способ предсказания терапевтического эффекта для пациентов с раком ободочной и прямой кишки с мутацией гена kras
Wu et al. A phase 3 study of first-line durvalumab vs platinum-based chemotherapy in patients with advanced NSCLC and high PD-L1 expression: PEARL
Yang A selective ALK inhibitor in ALK-rearranged patients
Reck et al. JAVELIN lung 100: updated design of a phase 3 trial of avelumab vs platinum doublet chemotherapy as first-line (1L) treatment for metastatic or recurrent PD-L1+ non-small-cell lung cancer (NSCLC)